Traders Purchase Large Volume of Intra-Cellular Therapies Put Options (ITCI)

Intra-Cellular Therapies Inc (NASDAQ:ITCI) was the recipient of unusually large options trading on Tuesday. Traders bought 674 put options on the company. This represents an increase of approximately 775% compared to the typical daily volume of 77 put options.

Shares of Intra-Cellular Therapies (ITCI) opened at $18.04 on Friday. Intra-Cellular Therapies has a twelve month low of $7.85 and a twelve month high of $22.67. The firm has a market capitalization of $981.31, a price-to-earnings ratio of -8.20 and a beta of 0.70.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.53). Intra-Cellular Therapies had a negative return on equity of 27.84% and a negative net margin of 74,375.35%. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.06 million. During the same quarter last year, the business posted ($0.70) EPS. Intra-Cellular Therapies’s revenue for the quarter was up 675.0% on a year-over-year basis. equities research analysts anticipate that Intra-Cellular Therapies will post -2.13 earnings per share for the current year.

ITCI has been the topic of a number of research analyst reports. ValuEngine downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 27th. Zacks Investment Research downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. SunTrust Banks raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Wednesday, November 8th. BidaskClub downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 12th. Finally, Canaccord Genuity initiated coverage on Intra-Cellular Therapies in a report on Friday, December 15th. They issued a “buy” rating and a $31.00 target price on the stock. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $26.00.

In other Intra-Cellular Therapies news, Director Christopher D. Alafi bought 10,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, November 22nd. The shares were purchased at an average price of $15.55 per share, with a total value of $155,500.00. Following the acquisition, the director now owns 744,466 shares in the company, valued at approximately $11,576,446.30. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Sharon Mates sold 6,604 shares of the firm’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $17.48, for a total value of $115,437.92. Following the completion of the sale, the chairman now directly owns 1,088,707 shares in the company, valued at approximately $19,030,598.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 49,410 shares of company stock worth $802,481. Corporate insiders own 19.80% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at $101,000. SG Americas Securities LLC acquired a new stake in shares of Intra-Cellular Therapies during the 2nd quarter valued at $103,000. Quantbot Technologies LP boosted its holdings in shares of Intra-Cellular Therapies by 233.1% during the 3rd quarter. Quantbot Technologies LP now owns 8,614 shares of the biopharmaceutical company’s stock valued at $135,000 after acquiring an additional 6,028 shares in the last quarter. Fred Alger Management Inc. acquired a new stake in shares of Intra-Cellular Therapies during the 2nd quarter valued at $161,000. Finally, Voya Investment Management LLC boosted its holdings in shares of Intra-Cellular Therapies by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 2,338 shares in the last quarter. 74.47% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Traders Purchase Large Volume of Intra-Cellular Therapies Put Options (ITCI)” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2018/01/21/traders-purchase-large-volume-of-intra-cellular-therapies-put-options-itci.html.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply